In this section
TA-GVHD is a rare but usually fatal complication of transfusion. The disease occurs when donor lymphocytes engraft in a susceptible recipient. These donor lymphocytes proliferate and damage target organs, especially bone marrow, skin, liver and gastrointestinal tract. Typically the condition presents 10-14 days after transfusion with rash (erythroderma), pancytopenia and abnormal liver function. There is a longer time between transfusion and presentation in neonates. The mortality rate of TA-GVHD approaches 100%.
The risk with an individual transfusion depends on a number of factors including, the viability of contaminating lymphocytes in the blood product, the susceptibility of the recipient's immune system to their engraftment, and the degree of immunologic disparity between the donor and recipient.TA-GVHD was originally recognised as a complication of intrauterine transfusion and transfusion to recipients of allogeneic bone marrow transplants. The most commonly reported setting for TA-GVHD is immunocompetent recipients of blood from biologically related (directed) or HLA identical donors.
The main stay of preventing TA-GVHD is gamma irradiation of blood products. Leukocyte depletion using current technology is inadequate for this purpose.
Irradiation of blood products is undertaken using a dedicated blood irradiator with a long half-life gamma emitting source.
Irradiation of red blood cells and whole blood results in reduced post transfusion red cell recovery and increases the rate of efflux of intracellular potassium. It has no clinically significant effect on red cell pH, glucose, 2,3 DPG levels or ATP. Packs irradiated within 14 days of collection expire 28 days after collection. Packs irradiated more than 14 days after collection expire either 5 days after irradiation OR at original expiry of pack, whichever comes first. In patients where hyperkalaemia is a concern, red cells should be transfused within 24 hours of irradiation. Examples include large volume neonatal transfusion such as exchange transfusion, ECMO or rapid large volume transfusion.
Irradiation of platelets has not been shown to cause any clinically significant change in platelet function. Platelets may be irradiated at any stage during their 5 day storage life. In Victoria all platelets are irradiated by ARCBS prior to issue.
Irradiation of granulocytes. There is conflicting evidence of irradiation damage to granulocytes. Granulocytes should be transfused as soon as possible after collection and irradiation.
Blood product irradiation is identified using the Radsure™ system. A label is applied to the blood pack prior to irradiation. The words NOT IRRADIATED are visible. Once irradiation has taken place, the word IRRADIATED remains visible.
The clinician requesting the crossmatch or blood product is responsible for ensuring irradiated components are requested for appropriate patients. Tick the box on the request form indicating irradiated products are required.
During the final bedside check prior to blood product administration, a check is made to ensure that appropriate blood product modifications such as irradiation or leukocyte depletion have been performed when requested by the treating clinician.
RCH blood bank has an onsite blood irradiator with a capacity for a single unit of red blood cells or whole blood and an irradiation time of 4 minutes 30 seconds. Red cell products are irradiated at the time of crossmatch or just prior to release for neonatal, intensive care and cardiac surgery patients.
At RCH a universal blood irradiation policy applies for patients in the following units: ICU, NNU, Haematology/Oncology. Although not all patients in these units are at risk of TA-GVHD, this policy ensures patients who require irradiated products are not missed.(Note - stem cells and bone marrow must not be irradiated).
In addition blood is irradiated at RCH in the following circumstances:
It is the clinicians responsibility to ensure that accurate clinical information appears on the request form or is communicated to the blood bank.